Bortezomib
€ Preis anfragen
Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity[1][2].
- CAS number: 179324-69-7
- Purity: 99.97
- Formula: C19H25BN4O4
- Solubility: DMSO : 50 mg/mL (ultrasonic)|Ethanol : 66.67 mg/mL (ultrasonic
- warming
- heat to 60°C)
- SMILES: OB(O)[C@H](CC(C)C)NC([C@@H](NC(C1=NC=CN=C1)=O)CC2=CC=CC=C2)=O
- Molecular Weight: 384.24
- Applications: Cancer-Kinase/protease
4°C (Powder, protect from light)
Ausgewählte Produkte
